Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19

Background: Nirmatrelvir-ritonavir received emergency use authorization (EUA) for the prevention of progression of COVID-19 in December 2021. Most data supporting this authorization are limited to the outpatient setting in unvaccinated patients, and high-quality head-to-head comparisons to other ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Dimple, Mccoy, Christopher, Donohoe, Kendall, Lee, Matthew, Gold, Howard, Chapin, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594325/
http://dx.doi.org/10.1017/ash.2023.297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594325/
http://dx.doi.org/10.1017/ash.2023.297

Ejemplares similares